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تشكيل طفرات/عمليات احلذف ل p53 يف جمموعة صغرية من العمانيني 
العمانيني املصابني باألورام الليمفاوية كبرية احلجم للخاليا البائية
يحيى �لتاميمي, �صيخة �حلارثي, �إبر�هيم �لهد�بي, حممد �لكندي, حمزة بابكر, من�صور �ملنذري, �إكر�م بريين
abstract: Objectives: Mutations/deletions affecting the TP53 gene are considered an independent marker 
predicting a poor prognosis for patients with diffuse large B-cell lymphoma (DLBCL). A cohort within a genetically 
isolated population was investigated for p53 mutation/deletion status. Methods: Deoxyribonucleic acid (DNA) 
samples were extracted from 23 paraffin-embedded blocks obtained from DLBCL patients, and subjected to 
polymerase chain reaction (PCR) amplification and sequencing of exons 4–9 of the p53 gene. Results: While 35% 
of patients analysed displayed allelic deletions (P <0.01), immunohistochemical analysis revealed a mutation rate 
of 69.5%. It is noteworthy that the rate of p53 mutations/deletions in this small cohort was found to be higher 
than that previously reported in the literature. Interestingly, patients with p53 mutations displayed a better overall 
survival when compared to those without. The survival of patients treated with rituximab-containing combination 
chemotherapy was significantly better than those who did not receive rituximab (P <0.05). Furthermore, a 
modelling analysis of the deleted form of p53 revealed a huge structural change affecting the DNA-binding domain. 
Conclusion: The TP53 mutation/deletion status plays a role in mechanism(s) ruling the pathogenesis of DLBCL 
and may be useful for stratifying patients into distinct prognostic subsets.
Keywords: Mutations; Gene Deletion; Lymphoma, B-Cell; Paraffin Embedding; Immunohistochemistry; Oman.
TP53 عالمة م�صتقلة للتنبوؤ �ل�صيء للمر�صى �مل�صابي باالأور�م �للمفاوية كبرية �حلجم  الهدف: تعترب �لطفر�ت/عمليات �حلذف �لتي مت�س  امللخ�ص: 
p53 لعينة من �ملر�صي �ملعزولي ور�ثيا و�لذين مت �ختيارهم لهذه  )DLBCL(. مت �ختبار�لطفر�ت/عمليات �حلذف للجي  �لبائية �ملنت�رشة  للخاليا 
�لدر��صة. الطرق: مت ��صتخر�ج مادة �حلم�س �لنووي )DNA( من 23مري�س و�لتي عر�صت للم�صاعفة عن طريق تفاعل �لبلمرة �ملت�صل�صل ومن ثم مت �يجاد 
 ,)P >0.01( النتائج: يف حي �أن %35 من �ملر�صى �لذين مت حتليلهم �أظهرو� حذفا �أليليا .p53 لت�صل�صل �لنيوكليوتيدي لالأك�صونات 9−4 من �جلي�
�لتي مت  �لعينة  �أن معدل �لطفر�ت/عمليات �حلذف للجي p53 يف  %69.5. ومن �جلدير بالذكر  �لن�صيجي معدل حتور بن�صبة  �لتحليل �ملناعي -  ك�صف 
در��صتها وجدت �أعلى مما هو موجود يف �لدر��صات �ل�صابقة. كما �أنه من �ملثري لالهتمام �أن �ملر�صى �لذين يحملون طفر�ت ب- p53 �أظهرو� فر�س يف �لبقاء 
علي قيد �حلياة بن�صب �أف�صل عند مقارنتهم بغريهم من �ملر�صى �لذين ال يحملون هذه �لطفر�ت. �أظهرت �لدر��صة �أي�صًا �أن �لبقاء على قيد �حلياة للمر�صى 
�لذين يعاجلون بعقار �لريتوك�صوماب �لعالج �لكيميائي �ملر كب �ملحتو ي �أ�صا�صا علي �لر يتو ك�صو ماب كان �أف�صل عند مقارنتهم باأولئك �لذين مل يتلقو� 
 .DNA تغيري� هيكليا كبري� يوؤثر يف جمال ربط �حلم�س �لنووي p53 عالوة على ذلك ك�صف حتليل �لنمذجة للحذف يف )P >0.05(.لريتوك�صيماب�
الإ�ستنتاج: ن�صتنتج �أن �لطفر�ت/عمليات �حلذف ل p53 تلعب دور� يف �الآليات �لتي حتكم �لت�صبب ب DLBCL كما �أنها ميكن �أن تكون مفيدة لتق�صيم 
�ملر�صى �إىل جمموعات فرعية للتنبوؤ بحالة �ملر�س.
مفتاح الكلمات: طفر�ت ور�ثية؛ عمليات �حلذف للجي؛ �الأور�م �لليمفاوية؛ �خلاليا �لليمفاوية �لبائية؛ �لتكتل بالبار�في؛ �لتحليل �ملناعي �لن�صيجي؛ عمان.
The p53 Mutation/Deletion Profile in a Small 
Cohort of the Omani Population with Diffuse 
Large B-Cell Lymphoma
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Advances in Knowledge 
- The TP53 mutation/deletion profile in the present study revealed a role in the mechanism(s) ruling the pathogenesis of diffuse large 
B-cell lymphoma (DLBCL) that might be useful for stratifying subpopulations based on their different genetic backgrounds.
Application to Patient Care
- The findings shed some light on the role of p53 mutations/deletions in mechanisms involved in the pathogenesis of DLBCL, which may 
help in stratifying affected patients into distinct prognostic subsets and in providing tailored therapies.
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Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL) in 
developing countries, including those in the Middle 
East, where it may constitute up to 60% of cases.1 
It has been shown that DLBCL is morphologically 
a very heterogeneous disease and the affected 
patients usually present with an advanced 
stage of the disease.1–3 Because of this complex 
heterogeneity, there is an unmet need to identify 
prognostic markers to help discriminate between 
DLBCL subgroups.
The p53 protein encoded by the p53 gene is 
a tumour suppressor gene playing a crucial role 
in cell cycle control, cell growth, apoptosis and 
senescence, and in the response to stress signals 
such as deoxyribonucleic acid (DNA) damage and 
hypoxia.4,5 Mutations of the p53 gene are common 
and have been implicated in the disease progression 
of more than 50% of epithelial cancers.6 
The normal functioning of the p53 gene 
is important for the eradication of tumours.7 
TP53 mutations are responsible for an increased 
resistance to chemotherapy, a decrease in apoptosis, 
neoangiogenesis and the early progression of the 
disease leading to a shortened overall survival rate.8 
In lymphoid malignancies, the incidence of p53 
mutations is reported to have a range of 5–25% of 
cases, the majority of which (~90%) are clustered in 
the DNA-binding domain of the protein.6–8 Other 
changes, such as single-nucleotide polymorphisms 
(SNPs), allelic loss and complete deletions between 
exons 4–9, have been also described.9
The prognostic value of TP53 mutations has not 
been consistent in DLBCL, where TP53 mutations 
are considered a poor prognostic factor.8,10–12 This 
inconsistency is likely due to the TP53 mutation’s 
heterogeneity, the limit of mutation detection 
methods or the diversity in the TP53 mutation’s 
functions.13,14
Rituximab, an anti-CD20 antibody, has improved 
the survival of patients with DLBCL significantly 
when combined with cyclophosphamide, 
hydroxydaunorubicin, oncovin and prednisolone 
(CHOP) chemotherapy, and acts through 
complement-mediated cytotoxicity and antibody-
dependent cellular cytotoxicity.15 High doses of 
rituximab inhibit cell growth through intracellular 
calcium (Ca2+) mobilisation. This is independent of 
the CD20 antigen and the inhibition of downstream 
key effectors such as protein 38, nuclear factor 
kappa-light-chain-enhancer of activated B cells, 
extracellular signal-regulated kinase, protein kinase 
B, and the downregulation of cytokine interleukin- 
10 and B-cell lymphoma-2 (BCL-2).15–17 Rituximab 
and other drugs can generate different stresses, 
affecting TP53 functioning. Similarly, the p53-
independent signalling pathways induced by 
rituximab can affect the transcription activity of the 
p53 gene. Thus, this lends validity to the importance 
of exploring the prognostic value of PT53 mutation/
deletion in patients with DLBCL treated with 
different drugs.
Studies on patients of Arab ethnicity in 
the Middle East describing p53 aberrations in 
DLBCL diseases are scarce; thus, this study aims 
to address the prognostic significance of p53 
mutation/deletions in a small cohort with DLBCL. 
Exons 4–9 of the p53 gene were analyzed using 
polymerase chain reaction (PCR), sequencing and 
immunohistochemical analysis on archival paraffin-
embedded material, and the mutation/deletion 
status was correlated with the clinical outcome. 
Additionally, molecular modelling was used to 
estimate the structural changes in the affected TP53 
protein. 
Methods
This study was approved by the Medical Ethics 
Research Committee of the College of Medicine 
& Health Sciences at Sultan Qaboos University, 
Muscat, Oman. Paraffin-embedded formalin-fixed 
tissue samples were obtained from Sultan Qaboos 
University Hospital. All of the samples were from 
Omanis diagnosed with stage IIB DLBCL or higher, 
according to the Ann Arbor system. The II stage 
indicates that either two or more lymph node 
regions on the same side of the diaphragm or one 
lymph node region and a contiguous extralymphatic 
site were involved, and the classification B indicates 
the presence of systemic symptoms. All the patients 
were treated between January 2001 and September 
2008. Table 1 outlines the histopathology and 
clinical data.
Paraffin blocks from 23 patients were 
examined by a pathologist and areas containing 
at least 95% cancer cells were marked and cut 
for DNA extraction. Serial sections of 8 μm were 
cut, deparaffinised in xylene and rehydrated in 
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decreasing ethanol concentrations of 100%, 70% 
and 50%. A digestion step in 20 mg/ml of proteinase 
K (Roche Diagnostic GmbH, Mannheim, Germany) 
was subsequently performed at 55 °C for at least 10 
hours. The tissues were then incubated overnight at 
55 °C in a lysis buffer solution (Tris(hydroxymethyl)
aminomethane pH 6.8, 20% sodium dodecyl sulfate 
(SDS) and 2% glycerol) (Fermentas, Thermo 
Fisher Scientific, Vilnius, Lithuania) and subjected 
to phenol chloroform extraction and ethanol-














57 F 4 4B Yes Extra-nodal 3 No mutation Dead
50 M 1 3B No Extra-nodal 2 No mutation Alive
20 M 3 4B Yes Extra-nodal 2 LOM in exons 4, 
5, 7 and 8
Alive
47 F 2 3A No Nodal 2 LOM in exons 4 
and 7–9
Alive
60 F - 4B Yes Extra-nodal 3 No mutation Dead
25 F 3 4B Yes Extra-nodal 3 LOM in exons 4, 5 
and 7–9
Alive
46 F 1 2B Yes Nodal - LOM in exons 4, 5 
and 7–9
Alive
70 M 3 3B Yes Nodal 1 No mutation Alive
66 M 4 3B Yes Nodal 3 No mutation Dead
50 F 3 3A No Extra-nodal 3 Mutation in 
exon 5
Dead
70 M 4 4B Yes Nodal 2 No mutation Dead
65 M - 4B Yes - 1 No mutation Dead
53 M 1 2B - - 1 LOM in exons 4, 5 
and 7–9
Alive
62 M 4 3B Yes Nodal 0 No mutation Dead
65 M 5 4A Yes Extra-nodal 2 No mutation Dead
48 M 4 4B - Extra-nodal 0 LOM in exons 4 
and 7–9
Alive
21 F - - - Nodal 2 LOM in exons 
4–9
Alive
21 F 3 2B Yes Extra-nodal 2 No mutation Alive
59 M - 4B Yes Nodal 2 No mutation Dead
29 M - - - - - - -
29 M - - - - 0 No mutation Alive
30 M - - - Nodal 0 Mutation and 
deletion in exon 5
Alive
70 M 5/5 4B Yes Extra-nodal 0 No mutation Alive
IPI = International Prognostic Index; B = presence of systemic symptoms; IHC = immunohistochemistry; LOM = loss of deoxyribonucleic acid 
material; F = female; M = male; IPI categories: Low risk (0–1 points) - 5-year survival 73%; Low-intermediate risk (2 points) - 5-year survival 51%; 
High-intermediate risk (3 points) - 5-year survival 43%; High risk (4–5 points) - 5-year survival 26%.
Stage II = cancer located in two separate regions, an affected lymph node or organ and a second affected area, and that both affected areas are 
confined to one side of the diaphragm.
Stage III = cancer has spread to both sides of the diaphragm, including one organ or area near the lymph nodes or the spleen.
Stage IV = diffuse or disseminated involvement of one or more extralymphatic organs, including any involvement of the liver, bone marrow, or 
nodular involvement of the lungs.
A = absence of constitutional (B-type) symptoms; B = presence of constitutional (B-type) symptoms.
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DNA precipitation. The DNA concentration was 
estimated with the NanoDrop method using a ND-
1000 spectrophotometer (NanoDrop Products, 
Thermo Scientific, Wilmington, Delaware, USA). 
Due to the extremely low concentration of normal 
cells present in each section composed of more 
than 90% of cancer cells, normal tissue could 
not be included for the control of sequencing 
reactions. This was corrected by taking sequences 
from normal blood as a reference for the putative 
polymorphisms. 
The extracted DNA was amplified by PCR 
using a set of designed primers covering the 
relevant areas of the p53 gene, including exons 
4–9. An additional pair of primers was used to 
amplify the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and to check 
for DNA integrity [Table 2]. In order to avoid 
primer mismatches that might result in negative 
PCR amplifications, all primers were checked for 
eventual mutations on their corresponding site. 
PCR reactions were performed in a total volume of 
50 μl using optimised PCR conditions. Each cycle 
was run through a denaturing step at 94 °C for 55 
secs, an annealing step ranging between 55–60 
°C for 55 secs (depending on the primers’ melting 
temperatures) and an elongation step of 55 secs at 72 
°C. The PCR reactions were run in a thermocycler 
for 25 cycles, preceded by a denaturing step of 4 
mins and followed by an extended elongation time 
of 7 mins at 72 °C. All amplification reactions were 
repeated at least twice to confirm the consistency of 
the PCR reactions.
Specific bands corresponding to the amplified 
PCR products were purified using the ExoSAP-
IT® enzyme clean-up method (Affymetrix, Inc., 
Santa Clara, California, USA), and the sequencing 
reactions were initiated using a BigDye Terminator 
(Applied Biosystems, Inc., Foster City, California, 
USA). After the ethanol precipitation, the DNA 
was resuspended in 10 μL of deionised formamide, 
covered and loaded into the sequencer ABI PRISM® 
3100 Genetic Analyzer (Applied Biosystems). 
Sequences were analysed using the SequencherTM 
4.7 software (Gene Codes Corporation, Ann Arbor, 
Michigan, USA).
For immunohistochemical staining, sections of 
4 μm were cut and mounted on polylysine-coated 
slides, dewaxed and placed in sodium perborate 
(0.2 M of disodium hydrogen phosphate, 0.3 M of 
monopotassium phosphate and 0.01 M of sodium 
chloride, at pH 9), then heated for 2–3 mins at 
100 °C in a microwave oven to mediate antigen 
retrieval. The machine was set up so that heating 
was controlled in order to ensure only the antigen 
retrieval, without causing tissue damage. A mouse 
monoclonal anti-human p53 antibody, recognising 
both the wild-type and the mutant p53 protein, was 
applied to the sections. The secondary antibody was 
an anti-mouse polyclonal conjugated to horseradish 
peroxidase (Dako A/S, Glostrup, Denmark) and 
used at 1/5000 dilution. The slides were visualised 
using the Universal Dako LSAB®+ Kit (Code K 
0679, Dako A/S) and scored by a pathologist. 
The positive cells were characterised by a brown 
precipitate at the cytoplasmic level as indicated by 
arrows in Figure 1B, whereas the negative cells were 
distinguished by their nuclear blue haematoxylin 
staining and an uncoloured cytoplasm. A cut-off 
value of p53 staining was set at 20% positive cells. 
Cases with no staining or less than 20% positive 
cells at x 400 magnification were scored zero. Cases 
of weak staining at x 400 magnification (more 
than 20% positive cells) were scored one, cases of 
moderate staining at x 100 magnification were 
scored two, and finally a score of three was given to 
cases with any percentage of staining recognisable 
at x 40 magnification. Sections displaying positive 
immunohistochemistry (IHC) staining were 
considered equivalent to p53 mutations. 
Clinicopathological variables such as age, 
gender, clinical stage, performance status, serum 
lactate dehydrogenase (LDH) levels and the site of 
disease were obtained from clinical reports. The 
number of extranodal sites was recorded and the 
patients were categorised using the International 
Prognostic Index (IPI). Overall survival was 
calculated from the time of diagnosis to death or 
until February 2011 using the Statistical Package for 
the Social Sciences (SPSS), Version 19 (IBM, Corp., 
Chicago, Illinois, USA) software. The minimum 
follow-up period was 30 months and the maximum 
was nine years. Median survival was estimated 
using the Kaplan-Meier method, and the log-rank 
test (Mantel-Cox test) was used for comparison 
among the different groups. The Fisher’s exact test 
was applied to estimate the putative association 
of mutations to the disease. One of the major 
limitations of this study was the small size of the 
cohort; the statistical methods used were therefore 
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carefully selected for small population sizes to avoid 
incorrect conclusions. 
Results
Paraffin blocks were available from 23 patients (15 
males and 8 females) with a median age at diagnosis 
of 49 years (range: 20–70 years). A complete clinical 
profile was available for 19 of the 23 patients only. 
Out of these 19 patients, two had stage IIB (as 
described previously) DLBCL, eight had stage III 
(indicating the involvement of lymph node regions 
on both side of the diaphragm), and nine had stage IV 
of the disease (indicating disseminated involvement 
of one or more extralymphatic organs). Using the 
IPI, two patients had a low to intermediate risk, 
whereas eight patients had a high to intermediate 
risk and nine patients a high risk [Table 1].
Out of the 21 patients with IHC staining scores, 
five displayed negative, three displayed weakly 
positive (score = 1), eight displayed moderately 
positive (score = 2) and five displayed strongly 
positive staining (score = 3). Figure 1 shows the 
p53 staining at different magnifications. Table 1 
summarises the IHC and sequencing data with the 
location of the aberration (mutation/deletion) and 
the DLBCL origin. PCR conditions were optimised 
using DNA extracted from healthy donor blood 
samples. All of the tested exons displayed single 
bands of an expected size, implying the specificity of 
the PCR reactions. The housekeeping gene GAPDH 
was run in parallel to verify the integrity of the DNA. 
The optimised conditions were applied to amplify 
the DNA samples [Figure 2]. A gel examination 
revealed extracted DNA of lower molecular weights 
and, therefore, it was difficult to amplify the large 
fragments (≥400 base pairs [bp]). Thus, primers 
generating lower size products were designed for 
both p53 and GAPDH. The PCR products were 
resolved using 1% agarose gel electrophoresis and 
all of the samples displayed specific bands of the 
expected sizes in exons 4, 5, 6 and 9. However, exon 
Figure 1 A & B: A representative example of the immunohistochemistry showing the positive and the negative staining 
obtained for (A) samples and (B) controls, respectively. The arrows indicate the stained cells at a magnification of x 40.
Figure 2: The optimisation of the polymerase chain reaction (PCR) conditions for exons 4–6 of the p53 gene. The 
polymerase chain reaction amplification products of exon 4 (lanes 1 and 2), exon 5 (lanes 4 and 5) and exon 6 (lanes 7 and 
8) of the p53 gene resolved on 1% agarose gel electrophoresis and compared to the 100 base pairs (bp) deoxyribonucleic 
acid marker (lane 1). Samples were run in duplicate, including the negative controls (lanes 3, 6 and 9).
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8 revealed either a complete absence of signals or 
faint bands (partial loss).
In the current study, eight samples highly 
amplified the GAPDH gene, but not the p53 gene, 
suggesting the presence of putative deletions [Figure 
3A–C]. To confirm this observation, samples were 
amplified from the OVCA2 gene located adjacent to 
the p53 gene on chromosome 17 and specific bands 
were obtained suggesting that the deletion is specific 
for the p53 gene. Moreover, in addition to the putative 
deletions observed, samples showing a high level of 
GAPDH but weak bands for the amplified exons 
4–9 were reported, representing typical examples 
of the partial loss of genetic material as shown in 
Figure 3B. The electropherogram revealed missense 
mutations in codon 143, changing the amino acid 
valine (non-polar) to leucine (non-polar) (GTG to 
TTA). In codon 145, missense mutations caused a 
change from the leucine (non-polar) to threonine 
(polar) amino acid (CTG to ACG). In codons 146 
and 150, there was a change from the tryptophan 
(non-polar) to the basic arginine (TGG to AGG) 
and from the threonine (polar) to arginine (ACA 
to AGA), respectively. Changing amino acids with 
different polarities may affect the functional profile 
of the mutated p53 protein.
The amino acid sequences of the p53 protein 
carrying the p53 mutation W150R and the sequence 
harbouring the deletion in exon 5 were subjected 
to a modelling analysis to predict the changes 
that occur in the p53 structure. Both aberrations 
(mutation and deletion) displayed an obvious 
change within the p53 three-dimensional structure 
(data not shown).
While the five-year survival rate was 48%, 
the median overall survival time was 57 months 
[Figure 4A]. The correlation of survival with the 
data obtained using IHC did not demonstrate any 
statistically significant difference between those 
with or without p53 mutations. However, patients 
with p53 mutations detected by sequencing 
demonstrated a trend of better overall survival 
compared to those who did not harbour mutations 
[Figure 4B]. Of the patients, 11 out of 19 received 
Figure 3 Panels A, B & C: The representative gel 
displaying the expression of the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene and exons 4–9 
of the p53 gene in samples 4, 13 and 16, respectively. The 
arrows indicate the obtained deletions (A & C) and 
partial loss (B). The partial loss is similar to gene dosage, 
where substantial deoxyribonucleic acid damage is 
obvious but not completely lost, likely resulting in far-
reaching repercussions on gene function.
Figure 4 A, B & C: The median overall survival curve. 
A: The overall survival plot displays the 57 months 
recorded for the studied cohort, while the five-year 
survival rate observed was 48%. B: However, the overall 
survival curve shows a trend towards better overall 
survival in patients who harboured mutations in the 
p53 gene, as analysed by sequence analysis. The 
immunohistochemistry analysis revealed no statistically 
significant difference between the survival of those with 
or without p53 mutations. C: The overall survival curve 
shows that patients receiving rituximab in addition to 
cyclophosphamide, hydroxydaunorubicin, oncovin and 
prednisolone (R-CHOP) did significantly better than 
those who only received CHOP (P <0.05).
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a combined therapy consisting of CHOP, whereas 
eight patients received the anti-CD20 antibody, 
rituximab, in addition to CHOP (R-CHOP). 
The survival of patients receiving R-CHOP was 
significantly better than those who received CHOP 
(P <0.05), as shown in Figure 4C.
Discussion
In this study, the entire region of the p53 gene, 
including exons 4–9, was screened for the presence 
of mutations/deletions; partial losses as well as 
deletions in eight of 19 patients were identified. 
To validate this observation, the OVCA2 gene 
localised in the neighbouring area of the p53 
gene on chromosome 17 was amplified. While no 
amplification of the p53 gene could be obtained 
using the p53 primers, specific bands were 
obtained systematically when the OVCA2 primers 
were used. Moreover, the p53 primers’ targeted 
area was meticulously scanned for the presence 
of any polymorphisms that might hamper the 
appropriate binding of the primers, resulting in 
non-amplified amplicons; however, no aberration 
was found. Southern blotting would have been 
more appropriate to confirm the deletions and 
loss of genetic material. However, the amount of 
DNA required for a Southern blot is substantial 
(more than 5 mg), and therefore difficult to obtain 
from archival material. Alternatively, confirming 
deletions by comparison of the housekeeping gene 
amplification of GAPDH with PCR products from 
the exons of interest is widely used.18
Faint bands were obtained by amplifying exons 
4, 5, 7 and 8 using the DNA from a patient with 
stage IV t-cell-rich DLBCL (t-DLBCL), suggesting 
that the loss of p53 material may be associated 
with the transformation of the disease. Another 
patient with stage IIB DLBCL displayed two faint 
bands for exons 5 and 6, while complete deletions 
were observed in exons 4, 7, 8 and 9 [Figure 3A–C]. 
Both patients displayed a positive staining by IHC. 
These data are in agreement with previous reports 
indicating that up to 20% of DLBCL patients 
harbour deletions on the short arm of chromosome 
17 (chromosome 17p13) corresponding to the 
location of the p53 gene.19 At the structural level, 
both the W150R mutation and the deletion in exon 4 
displayed substantial changes in the p53 gene when 
compared to the wild-type molecule. Changing the 
non-polar amino acid tryptophan (W) at position 
150 by the larger polar arginine amino acid (R), 
within a well-conserved region (from amino acid 
101 to 306) containing the DNA-binding domain, 
would likely alter the tumour-suppressing function 
of the p53 protein. The predicted model of the 
p53-exon-4-deleted form revealed an obviously 
disorganised structure of the p53 protein affecting 
several domains, including the transactivation and 
the binding domains.
Both the quantitative PCR and Southern blotting 
methods have revealed deletions in relevant genes in 
DLBCL such as CDKN2 and CDKN2B.20 Moreover, 
a substantial decrease in messenger ribonucleic acid 
(mRNA) expression levels associated with specific 
gene signatures has been confirmed with gene 
deletion.21 Interestingly, these deletions were directly 
associated with a poor prognosis in DLBCL.20–23 A 
deletion on the short arm of chromosome 17 may 
be a sign of transformation from other types of 
lymphoma to DLBCL.19 Moreover, it was reported 
that p53 mutations and deletions are detected 
in t-DLBCL and predict resistance to treatment 
and short survival in variants of DLBCL.24,25 The 
transformation of follicular lymphoma can evolve 
through a variety of mechanisms characterised by a 
high proliferation rate and the mutation of the p53 
gene, amplification of the REL gene, loss of CDNK2A 
and changes in the c-myc gene expression.26
Missense mutations in exon 5 were found 
in two patients, one of whom presented with 
extranodal t-DLBCL at stage III of the disease. The 
IHC analysis showed a positive staining, which is 
consistent with sequence analysis data. The second 
patient had a similar pattern with deletions in exons 
4, loss of material in exon 7 and a C to T point 
mutation in exon 5, changing the proline amino 
acid to serine at position 177 (P 177 S). No positive 
staining, however, was revealed by IHC. This could 
be explained by a large deletion in the p53 gene that 
may hamper transcription. The missense mutation 
found in exon 5 was located on the DNA-binding 
domain of the p53 protein, which is divided into 
three loops (L1, L2 and L3) and two loop sheet helix 
(LSH) regions. L1, L3 and LSH make direct contact 
with the DNA while L2 is required for the folding 
and stabilisation of the DNA-binding domain, with 
no direct contact with the DNA.8 The missense 
mutation on exon 5 is located in the core domain 
within L2 and L3. Therefore, this could affect both 
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the DNA binding and the folding process of the 
related domain. It was found that mutations within 
areas of direct contact with the DNA resulted in a 
poor survival rate, while mutations that affected the 
folding of the protein had no significant impact on 
the patient’s overall survival.8
Positive staining was shown in ten patients by 
IHC; however, no aberrations were detected by 
sequencing. This contradiction is likely due to the 
limited area covered by the sequencing, omitting 
some exons (for instance exons 1–3) as well as 
the promoter area, also frequently targeted by 
mutations. Moreover, the IHC technique cannot 
be used alone to predict mutations since the 
mechanisms responsible for gene overexpression 
may generate false-positive results.27 On the other 
hand, protein-stabilising factors such as the MDM2 
protein could have an effect by promoting the rapid 
degradation of the phosphorylated form of p53.28 
The p53 gene activates the expression of MDM2 
in an auto-regulatory feedback loop. Therefore, 
mutations affecting MDM2 cause a half-life increase 
of the p53 protein and its accumulation, allowing its 
detection by IHC.29 
Unexpectedly, a better overall survival rate for 
patients harbouring p53 mutations was observed 
when compared with patients with no mutations 
in the p53 gene. Data concerning this matter are 
conflicting.9,11,30,31 For instance, Ichikawa et al. 
demonstrated that the overall survival was inferior 
for an entire cohort with p53 mutations. However, 
this effect was not seen in patients with a high-risk 
IPI category.11 In the current study, at presentation 
all but two patients had a high to intermediate and 
high risk IPI category. An alternative explanation 
could be related to the effect of treatment. As 
shown in Figure 4C, patients treated with R-CHOP 
had a higher overall survival compared to those 
who were treated with CHOP alone. The p53-
induced apoptotic pathway could be overhauled as 
a result of mutations in the p53 gene. Conversely, 
rituximab inhibits the anti-apoptotic protein 
BCL-2, thus causing apoptosis induction. It is 
plausible that rituximab-induced apoptosis may 
override the mutant p53-mediated anti-apoptotic 
pathway. Similarly, Hussein et al. showed a negative 
correlation between BCL-2 and p53 protein 
expression in lympho-proliferative disorders.32 
In a recent report, Xu-Monette et al. studied the 
prognostic significance of p53 mutations in DLBCL 
using a large cohort of de novo DLBCL patients 
treated with R-CHOP, and showed that those with 
TP53 mutations had worse overall and progression-
free survival compared to those without.33 It is 
worth noting that the majority of studies on the 
association of p53 with prognosis in DLBCL are 
from the pre-rituximab era.
Data reporting on the DLBCL incidence in 
the Middle East and comparisons to those in 
Western countries, including North America, 
are scarce. However, Ameen et al. studied NHL 
frequency among different ethnic groups in Kuwait 
and compared those results with studies from 
the Western world. They found that the Kuwaiti 
population had a higher prevalence of DLBCL and 
extranodal presentation.34 Despite the small number 
of patients recruited, the data on Omani patients 
in this study are in agreement with the increase of 
DLBCL frequency in the Middle East region; the 
aberrations (mutation/deletion) of the p53 gene 
might be directly linked to this higher frequency.
Despite several tentative attempts, we were 
unable to increase the number of samples used 
for this study which was a major limitation. 
Precautions were taken throughout and the small 
size of the sample was taken into account by using 
the appropriate statistical methods. 
Conclusion 
Mutations/deletions were frequently detected 
within the relevant region of the p53 gene. The 
incidence of mutations was higher than those 
previously reported in the literature and may suggest 
that the biology of the disease changes depending 
on ethnicity. The survival data, especially with 
regards to potential treatment, are intriguing and 
require verification in a larger cohort. The number 
of patients recruited for this study was very modest 
and analysis should be extended to a large cohort in 
order to  draw appropriate conclusions.
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